NOVARTIS
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
Effects of Multiple Nasal Exposures to House Dust Mite Allergen on Nasal and Body Inflammation and Airway Sensitivity
- Conditions
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2008-07-15
- Lead Sponsor
- Novartis
- Target Recruit Count
- 18
- Registration Number
- NCT00513487
- Locations
- 🇦🇺
Novartis Investigative site, Sydney, Australia
A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation
- First Posted Date
- 2007-08-06
- Last Posted Date
- 2010-11-18
- Lead Sponsor
- Novartis
- Registration Number
- NCT00511771
Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2007-08-02
- Last Posted Date
- 2012-05-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 281
- Registration Number
- NCT00510510
- Locations
- 🇹🇷
Novartis investigative site, Istanbul, Turkey
Efficacy and Safety of Subcutaneous Versus Intravenous ACZ885 in Adult Patients With Established Rheumatoid Arthritis
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2009-08-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 11
- Registration Number
- NCT00505089
- Locations
- 🇵🇱
Novartis Investigative Site, Grodzisk Mazowiecki, Poland
🇳🇱Novartis investigative site, Leiden, Netherlands
🇵🇱Novartis Investigator Site, Poznan, Poland
Safety and Efficacy of ACZ885 in Adult Patients With Established Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 80
- Registration Number
- NCT00504595
- Locations
- 🇨🇭
Novartis Investigative site, Bern, Switzerland
🇹🇷Novartis investigative site, Istanbul, Turkey
Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2016-03-04
- Lead Sponsor
- Novartis
- Target Recruit Count
- 234
- Registration Number
- NCT00504959
- Locations
- 🇹🇷
Novartis Investigative SIte, Ankara, Turkey
🇦🇺Novartis Investigational Site, Melbourne, Australia
🇬🇧Novartis Investigative Site, Wolverhampton, United Kingdom
Tolerability, Safety and Efficacy of SAD448 in Subjects With Ocular Hypertension
- Conditions
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2008-04-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 80
- Registration Number
- NCT00503360
- Locations
- 🇦🇺
Novartis Investigative site, Sydney, Australia, Sydney, Australia
Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration
- Conditions
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2007-12-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 20
- Registration Number
- NCT00503022
Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.
- Conditions
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2011-06-02
- Lead Sponsor
- Novartis
- Target Recruit Count
- 155
- Registration Number
- NCT00500539
- Locations
- 🇺🇸
Kansas City Allergy & Asthma, Overland Park, Kansas, United States
🇺🇸Allergy, Asthma and Clinical Immunology, Brick, New Jersey, United States
🇺🇸Asthma & Allergy Research of NJ, Inc., Mt. Laurel, New Jersey, United States
Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension
- Conditions
- Interventions
- First Posted Date
- 2007-07-10
- Last Posted Date
- 2014-09-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 46
- Registration Number
- NCT00498433
- Locations
- 🇩🇪
Novartis Investigative Site, Hannover, Germany